HUPO and IUBMB Merge Meetings
The Human Proteome Organization and the International Union of Biochemistry & Molecular Biology said this week that they were going to merge HUPO’s 2nd Annual World Congress and IUBMB’s 19th International Congress. The combined HUPO-IUBMB meeting will take place October 8-11 in Montreal, Canada. IUBMB’s meeting, originally scheduled for July 20-24 in Toronto, was cancelled last month due to SARS fears.
Indiana Proteomics Becomes Inproteo
The Indiana Proteomics Consortium has renamed itself Inproteo.
Besides seeking a shorter name, “we wanted something that is more reflective of our focus on for-profit, reflective of our proteomics focus, and perhaps not being so obviously focused on Indiana,” John Hurrell, Inproteo’s president, told ProteoMonitor.
The consortium was founded in February 2002 by Indiana University, Purdue University, and Eli Lilly to develop novel instrumentation and methodologies in proteomics.
Bruker & Bruker Complete Merger
Bruker Daltonics and Bruker AXS completed their merger this week to become Bruker BioSciences. Shareholders approved the merger last Friday with 94 percent of the stockholders of each company voting in favor. The new company began trading under the Nasdaq symbol, BRKR, on July 2.
Cohesive Technologies to Use Series B Investment for Proteomics Program
Cohesive Technologies of Franklin, Mass., announced this week that it had received $9.5 million in a Series B financing led by Psilos Group Partners.
The company, which makes and markets liquid chromatography systems, hopes to use the money in part to “launch new programs in proteomics, protein purification, and diagnostics,” according to president and CEO Peter Glick.
AGY Collaborates with Cengent for X-ray Crystallography
Cengent Therapeutics of San Diego, Calif., which was created in May from the merger of Structural Bioinformatics and GeneFormatics, said this week that it is lending its X-ray crystallography capabilities to San Francisco-based AGY Therapeutics.
AGY, which develops drugs to treat diseases of the central nervous system, hopes to use Cengent’s technology to improve its structure-based lead optimization capabilities.
ActivX Wins $1.1 Million SBIR Phase II Grant for Toxicity Database
ActivX Biosciences of La Jolla, Calif. said this week that it received a $1.1 million Small Business Innovation Research Phase II grant from the National Cancer Institute. The three-year grant follows on the heels of a six-month, $155,000 SBIR Phase I grant awarded in August 2002.
The first grant funded the initiation of ActivX’s drug toxicity profiling program.The new grant, which provides $493,000 for the first year and $558,000 for the second year, will primarily be used to establish a database of changes in protein activity resulting from toxicant exposure, according to the company. Scientists will compare protein activity in response to lead compounds to that resulting from toxins recorded in the database, allowing them to more quickly and accurately determine the lead’s possible toxic effects.
This information will be used to evaluate candidate drug compounds for diseases of interest to the NCI, the National Institute for Diabetes, Digestive and Kidney Disorders, and the National Institute for Drug Abuse. ActivX will retain worldwide rights to any inventions made in the course of this project.
GWC Receives Second $100K NSF Award
GWC Technologies of Madison, Wis., said it has received a $99,800 Small Business Innovation Research award from the NSF to develop its biochip program.
This is the second NSF award in two weeks for GWC; the first, for $99,724, was earmarked for the development of GWC’s FT-SPR systems (see PM 6-27-03).
Fisher Scientific to Acquire Perbio Science in $714M Deal
Fisher Scientific, of Hampton, NH, announced last week that it would acquire Helsingborg, Sweden-based Perbio Science for approximately $714 million.
Perbio manufactures a variety of cell culture and bioresearch products, including protein quantification, purification and modification kits, as well as high-throughput screening and protein profiling tools. Completion of the deal will depend upon a 90 percent shareholder acceptance and is expected to close in mid-August, according to the companies.